Michel Detheux, iTeos» Chief Executive Officer added, «The progress of our adenosine A2A antagonist program demonstrates how we can rapidly apply
our expertise in medicinal chemistry, tumor immunology and translational medicine to advance candidates toward clinical development.»
He believes the researchers and labs collaborating on the project are particularly well suited to take on the challenge, bringing to bear
expertise in organic and
medicinal chemistry (Fasan), drug delivery technologies (Benoit), and the physiopathology of bone marrow during myeloid malignancy (Frisch).